Edition:
India

Biohaven Pharmaceutical Holding Company Ltd (BHVN.N)

BHVN.N on New York Stock Exchange

27.10USD
25 Apr 2018
Change (% chg)

$0.67 (+2.54%)
Prev Close
$26.43
Open
$26.37
Day's High
$27.36
Day's Low
$25.60
Volume
54,418
Avg. Vol
138,393
52-wk High
$39.20
52-wk Low
$16.51

Latest Key Developments (Source: Significant Developments)

Biohaven restructures license agreement with Bristol-Myers Squibb to reduce royalties payable on its migraine product candidates
Monday, 12 Mar 2018 

March 12 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd ::BIOHAVEN RESTRUCTURES LICENSE AGREEMENT WITH BRISTOL-MYERS SQUIBB TO REDUCE ROYALTIES PAYABLE ON ITS MIGRAINE PRODUCT CANDIDATES; TRANSACTION FINANCED THROUGH PRIVATE PLACEMENT WITH LEADING INSTITUTIONAL INVESTORS.BIOHAVEN PHARMACEUTICAL-CO TO PAY BMS UPFRONT PAYMENT OF $50 MILLION IN RETURN FOR LOW SINGLE DIGIT REDUCTION IN ROYALTIES ON NET SALES OF RIMEGEPANT​.BIOHAVEN PHARMACEUTICAL HOLDING COMPANY - ‍UPFRONT PAYMENT FOR RESTRUCTURING FINANCED THROUGH PRIVATE PLACEMENT OF CO COMMON SHARES TO INVESTORS​.BIOHAVEN PHARMACEUTICAL HOLDING COMPANY - ‍BIOHAVEN'S OBLIGATIONS TO MAKE DEVELOPMENT AND COMMERCIAL MILESTONE PAYMENTS TO BMS REMAIN UNCHANGED​.BIOHAVEN PHARMACEUTICAL HOLDING - ‍RESTRUCTURING OF AGREEMENT WITH BRISTOL-MYERS FOR SMALL MOLECULE CALCITONIN GENE-RELATED PEPTIDE RECEPTOR ANTAGONIST PLATFORM​.BIOHAVEN PHARMACEUTICAL HOLDING CO - CO WILL PAY BMS $50 MILLION IN RETURN FOR A MID-SINGLE DIGIT REDUCTION IN ROYALTIES PAYABLE ON NET SALES OF BHV-3500​.BIOHAVEN PHARMACEUTICAL-‍RESTRUCTURING WAS FINANCED THROUGH A $55 MILLION PRIVATE PLACEMENT OF 2 MILLION BIOHAVEN COMMON SHARES AT A PRICE OF $27.50 PER SHARE​.  Full Article

Biohaven Pharmaceutical Q4 Loss Per Share $0.75
Wednesday, 7 Mar 2018 

March 6 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd ::BIOHAVEN PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL AND BUSINESS RESULTS.Q4 LOSS PER SHARE $0.75.  Full Article

Biohaven Says Expects Topline Results From Phase 3 Trial With Rimegepant Zydis ODT In Q4​
Tuesday, 6 Mar 2018 

March 6 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd ::BIOHAVEN ENROLLS FIRST PATIENT IN PHASE 3 CLINICAL TRIAL TO EVALUATE RIMEGEPANT ZYDIS® ODT IN THE ACUTE TREATMENT OF MIGRAINE.BIOHAVEN - CONTINUES TO EXPECT TOPLINE RESULTS FROM TWO PHASE 3 TRIALS EXAMINING EFFICACY OF RIMEGEPANT 75 MG ORAL TABLET VERSUS PLACEBO BY END OF Q1 2018​.BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD SAYS ‍EXPECTS TOPLINE RESULTS FROM PHASE 3 TRIAL WITH RIMEGEPANT ZYDIS(®) ODT IN Q4 OF 2018​.  Full Article

Biohaven Completes Enrollment In Second Pivotal Phase 3 Clinical Trial Of Oral CGRP-Receptor Antagonist Rimegepant
Monday, 27 Nov 2017 

Nov 27 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd ::BIOHAVEN COMPLETES ENROLLMENT IN SECOND PIVOTAL PHASE 3 CLINICAL TRIAL OF ORAL CGRP-RECEPTOR ANTAGONIST RIMEGEPANT.  Full Article

Biohaven Pharma qtrly loss per share $1.19‍​
Wednesday, 15 Nov 2017 

Nov 14 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd :Biohaven pharmaceuticals reports third quarter 2017 financial and business results.Biohaven pharmaceutical holding company ltd - qtrly loss per share $1.19‍​.  Full Article

Biohaven announces FDA clearance of IND application for sublingual BHV-0223
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd :Biohaven announces FDA clearance of IND application for sublingual bhv-0223 in patients with amyotrophic lateral sclerosis (ALS).‍U.S. FDA has notified that co may proceed with clinical investigation of sublingual bhv-0223 ​.Expects to submit an IND to FDA by end of this year for BHV-3500 for treatment of migraine​.Expects to commence a Bioequivalence study of BHV-0223 in the current quarter.  Full Article

Biohaven receives FDA may proceed letter for phase 2/3 clinical trial of Trigriluzole
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd :Biohaven receives FDA may proceed letter for phase 2/3 clinical trial of Trigriluzole in patients with obsessive-compulsive disorder.U.S. Food and drug administration (FDA) has notified co that it may proceed with its clinical investigation of Trigriluzole​.Expects to commence a phase 2/3 clinical trial of Trigriluzole in OCD in the current quarter.‍expects to report topline results in Q1 of 2018 for acute treatment of migraine​.Data from long-term safety study is expected to support a potential NDA submission in first half of 2019​.‍Also expects to file an IND with FDA by end of this year for BHV-3500 for treatment of migraine​.Anticipates commencing bioequivalence study for bhv-0223 for treatment of patients with ALS in Q4.  Full Article

Biohaven enters two separate subscription agreements with Kleo
Friday, 13 Oct 2017 

Oct 12 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd :Biohaven Pharmaceutical- ‍on Oct 5, co entered two separate subscription agreements with Kleo to maintain co's relative ownership interest in Kleo​.Biohaven Pharmaceutical - ‍pursuant to first subscription agreement, co purchased 1.4 million shares of Kleo's common stock at $1.0993 per share.Biohaven says ‍pursuant to second subscription agreement, co bought additional 651,639 shares of Kleo's common stock at $1.0993 per share​- SEC filing.  Full Article

Biohaven reports negative topline data from degenerative, genetic disease phase 2/3 trial
Monday, 2 Oct 2017 

Oct 2 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd : :Biohaven reports negative topline data from spinocerebellar ataxia (sca) phase 2/3 trial.Biohaven Pharmaceutical Holding Company Ltd - ‍trigriluzole did not differentiate from placebo on primary endpoint or key secondary outcome​.Biohaven Pharmaceutical Holding Company Ltd - ‍trigriluzole was well tolerated and safely administered in study population​.Biohaven pharmaceutical - co affirms robust recruitment of its two phase 3 cgrp antagonist efficacy trials and expects topline results in q1 of 2018.Biohaven Pharmaceutical-for both cgrp phase-3 studies ‍long-term safety study expected to complete in q4 2018 to support potential h1 2019 nda submission​.Biohaven pharmaceutical holding company ltd - ‍biohaven also expects to file an ind with fda later this year for bhv-3500 for treatment of migraine​.Biohaven Pharmaceutical - expects to commence bioequivalence study for bhv-0223 for treatment of patients with amyotrophic lateral sclerosis in q4 2017.  Full Article

Biohaven Pharmaceuticals Q2 loss per share ‍$1.78​
Monday, 14 Aug 2017 

Aug 14 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd :Biohaven Pharmaceuticals reports second quarter 2017 financial and business results.Qtrly loss per share ‍$1.78​.Biohaven Pharmaceuticals- ‍cash as of June 30, 2017 was $204.3 million, compared to $52.3 million as of March 31, 2017​.  Full Article